Contraindications to thrombolytic therapy
Contraindications to thrombolytic therapy for patients with STEMI can be absolute or relative; see Contraindications to thrombolytic therapy in ST elevation myocardial infarction. Patients with an absolute contraindication should be transferred for PCI. For patients with a relative contraindication, consider the risks and benefits of treatment, and seek specialist advice.
Absolute contraindications [NB1]
- any prior intracranial haemorrhage
- known structural cerebral vascular lesion (eg arteriovenous malformation)
- known malignant intracranial neoplasm (primary or metastatic)
- ischaemic stroke within 3 months, except acute ischaemic stroke within 4.5 hours
- suspected aortic dissection
- active bleeding or bleeding diathesis (excluding menses)
- significant closed head or facial trauma within 3 months
Relative contraindications [NB1]
- history of chronic, severe, poorly controlled elevated blood pressure
- severely elevated blood pressure on presentation (more than 180 mmHg systolic or more than 110 mmHg diastolic)
- ischaemic stroke more than 3 months ago, dementia, or known intracranial abnormality not covered as an absolute contraindication
- traumatic or prolonged (more than 10 minutes) cardiopulmonary resuscitation
- recent (within 3 weeks) major surgery
- recent (within 4 weeks) internal bleeding (eg gastrointestinal or urinary tract haemorrhage)
- noncompressible vascular punctures in the past 24 hours (eg liver biopsy, lumbar puncture)
- pregnancy or within 1 week postpartum
- active peptic ulcer disease
- current use of anticoagulants
- advanced liver disease
- infective endocarditis
- transient ischaemic attack in the preceding 6 months
NB1: This is not an exhaustive list; assess each patient individually.
Source: O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362-425. URL